AtriCure (NASDAQ:ATRC) Upgraded to Strong-Buy at Zacks Research

Key Points

• Zacks Research upgraded AtriCure from Hold to Strong Buy. Analyst sentiment is broadly positive, with MarketBeat reporting a Moderate Buy consensus and an average price target of $61.80.
• Quarterly results beat expectations: AtriCure reported EPS of $0.17 versus consensus for a $0.06 loss and revenue of $154.45 million versus estimates of $151.05 million. The company also raised its 2026 revenue outlook to $606 million–$610 million.
• Analysts including BTIG raised price targets, but views remain mixed: UBS downgraded the stock to Sell and JPMorgan kept a Neutral rating. AtriCure shares have also risen sharply, prompting concerns that optimism may already be reflected in the valuation.

AtriCure (NASDAQ:ATRC - Get Free Report) was upgraded by equities researchers at Zacks Research from a "hold" rating to a "strong-buy" rating in a report issued on Wednesday, Zacks reports.

A number of other equities analysts have also recently commented on ATRC. BTIG Research lifted their price objective on shares of AtriCure from $63.00 to $70.00 and gave the stock a "buy" rating in a research note on Wednesday. UBS Group downgraded shares of AtriCure from a "buy" rating to a "sell" rating in a report on Wednesday, October 21st. Citizens Jmp upped their target price on shares of AtriCure from $52.00 to $68.00 and gave the company a "market outperform" rating in a research report on Wednesday, October 21st. JPMorgan Chase & Co. increased their price target on shares of AtriCure from $36.00 to $62.00 and gave the company a "neutral" rating in a report on Wednesday. Finally, Freedom Capital lowered AtriCure from a "strong-buy" rating to a "hold" rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $61.80.

AtriCure Price Performance

Shares of AtriCure stock opened at $61.28 on Wednesday. The firm has a market cap of $3.12 billion, a PE ratio of 159.83 and a beta of 1.23. The stock has a 50 day moving average of $56.62 and a 200 day moving average of $38.63. The company has a current ratio of 4.33, a quick ratio of 3.19 and a debt-to-equity ratio of 0.11. AtriCure has a 12 month low of $25.36 and a 12 month high of $66.02.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.23. The business had revenue of $154.45 million for the quarter, compared to the consensus estimate of $151.05 million. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. On average, research analysts expect that AtriCure will post 0.29 EPS for the current fiscal year.

Insider Activity at AtriCure

In other AtriCure news, insider Salvatore Privitera sold 8,404 shares of AtriCure stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $65.00, for a total transaction of $546,260.00. Following the completion of the transaction, the insider directly owned 134,341 shares of the company's stock, valued at $8,732,165. The trade was a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Karl S. Dahlquist sold 9,370 shares of the business's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the transaction, the insider owned 87,319 shares in the company, valued at $4,269,025.91. This trade represents a 9.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 39,026 shares of company stock worth $2,172,263. Company insiders own 4.00% of the company's stock.

Institutional Investors Weigh In On AtriCure

Institutional investors have recently made changes to their positions in the company. Fifth Third Bancorp lifted its position in shares of AtriCure by 488.6% during the third quarter. Fifth Third Bancorp now owns 11,543 shares of the medical device company's stock worth $649,000 after purchasing an additional 9,582 shares during the last quarter. Maryland State Retirement & Pension System bought a new position in shares of AtriCure in the third quarter worth about $639,000. Lisanti Capital Growth LLC bought a new position in shares of AtriCure in the third quarter worth about $4,460,000. Fulcrum Asset Management LLP purchased a new position in AtriCure in the 3rd quarter worth about $92,000. Finally, Brighton Jones LLC purchased a new position in AtriCure in the 3rd quarter worth about $279,000. Institutional investors own 99.11% of the company's stock.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of the $0.06-per-share loss analysts expected, while revenue of $154.45 million also topped estimates. AtriCure raised its 2026 revenue guidance to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. AtriCure reports third-quarter results AtriCure outlook and study enrollment
• Positive Sentiment: Several analysts raised price targets following the results. Piper Sandler reiterated Overweight and raised its target to $70; Needham also set a $70 target, while Canaccord raised its target to $67 with a Buy rating. These revisions signal continued confidence in AtriCure’s growth prospects. Analysts raise forecasts Piper Sandler rating
• Neutral Sentiment: JPMorgan raised its target substantially, to $62, but maintained a Neutral rating—suggesting limited upside in its view. JPMorgan rating and target
• Negative Sentiment: A valuation-focused article questioned whether strong results and the higher outlook are already reflected in the stock, which could constrain further gains after its recent run-up. AtriCure valuation discussion
• Negative Sentiment: Insider Salvatore Privitera sold 8,404 shares for about $546,000. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 134,341 shares, making the signal less concerning than an unplanned sale. SEC insider filing

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company's product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.